The CHAMP-study: The CHemopreventive Effect of Lithium in Familial AdenoMatous Polyposis

PHASE2CompletedINTERVENTIONAL
Enrollment

12

Participants

Timeline

Start Date

June 2, 2022

Primary Completion Date

September 30, 2024

Study Completion Date

September 30, 2024

Conditions
Familial Adenomatous Polyposis
Interventions
DRUG

Lithium Carbonate

Patients will be administered lithiumcarbonate by an oral tablet of 300mg once a day for a duration of 6 months. Starting dose is 200mg for the first 5 days, dosage will be then increased to 300mg. To limit adverse events and side-effects, the lowest effective dose will be administered. The target serum level of lithium is 0.20 - 0.40 mmol/L and this will be maintained by regular lithium level testing.

Trial Locations (1)

1105AZ

Academic Medical Centre, Amsterdam

All Listed Sponsors
lead

Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)

OTHER